Citi Pharma reports higher quarterly profit and EPS
Financial ResultCiti Pharma Limited reported consolidated revenue of Rs. 3.514 billion and profit attributable to owners of Rs. 248.792 million for the quarter ended September 30, 2026. Compared with the same quarter last year, revenue, operating profit, net profit and EPS were higher.
Key Findings
- Revenue increased to Rs. 3,514,442,888 from Rs. 3,370,247,671.
- Operating profit increased to Rs. 511,162,226 from Rs. 420,355,037.
- Profit attributable to owners rose to Rs. 248,792,484 from Rs. 203,690,873.
- EPS increased to Rs. 1.09 from Rs. 0.89.
Financial Performance
| Metric | PreviousQuarter ended September 30, 2025 | CurrentQuarter ended September 30, 2026 | Change |
|---|---|---|---|
| Sales - net | 3,370,247,671 | 3,514,442,888 | +4.3% |
| Gross profit | 518,973,622 | 674,262,488 | +29.9% |
| Operating profit | 420,355,037 | 511,162,226 | +21.6% |
| Profit attributable to owners of the Holding Company | 203,690,873 | 248,792,484 | +22.1% |
| Earnings per share - basic and diluted (Rupees) | 0.89 | 1.09 | +22.5% |
| Financial charges | (121,191,504) | (100,672,701) | -16.9% |
| Cash and bank balances | 208,822,019 | 270,807,545 | +29.7% |
| Short term borrowings | 2,869,594,957 | 2,856,035,136 | -0.5% |
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.



